On August 18, 2021, ICER released its draft evidence report, “Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value.” This guide provides a framework for considering what aspects of the new hypertrophic cardiomyopathy treatment are important to patients and their families, and how to consider presenting those perspectives.
